Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EUCLID PAD trial of ticagrelor versus clopidogrel
2011-004616-36Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in arteriosclerosis obliterans comparing Ticagrelor with Clopidogrel (2 arms). Primary endpoint: Composite of cardiovascular death, myocardial infarction, and ischemic stroke. Started Sep 2012; status: completed.
02
Drugs
ticagrelorclopidogrel
03
Conditions
arteriosclerosis obliterans
Beyond the preview
Go deeper on 2011-004616-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004616-36.